A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection
Status:
Completed
Trial end date:
1990-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical and laboratory toxicity of ganciclovir (GCV) and zidovudine (AZT)
when given in combination.
Because recent information has shown AZT to be useful in treating AIDS, it is assumed that
most patients with AIDS, and probably with AIDS related complex (ARC), will be receiving AZT.
Because AZT is reported not to be active against cytomegalovirus (CMV), it is important to
see if it is useful to give GCV along with AZT.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)